Literature DB >> 2901663

Opiate binding in calf thalamic membranes: a selective mu 1 binding assay.

J A Clark1, R Houghten, G W Pasternak.   

Abstract

In the present study, we examined the binding of [3H][D-Ala2,D-Leu5]enkephalin ([ 3H]DADL) to bovine thalamic membranes. Scatchard plots were linear with a KD of 0.7 nM. However, competition experiments suggested binding heterogeneity. Approximately 20% of [3H]DADL binding was easily inhibited by [D-Pen2,D-Pen5]enkephalin (DPDPE) and was insensitive to morphine, implying labeling of delta receptors. The remaining 80% of binding was quite sensitive to both morphine and [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAGO) and insensitive to DPDPE, consistent with a mu receptor. However, this binding did not correspond to classical morphine-selective mu receptors. Unlike morphine-selective receptors, this binding had similar affinities for morphine, DAGO, DADL and [D-Ser2,Leu5]enkephalin-Thr6 (DSLET). In addition, it was far more sensitive to naloxonazine's wash-resistant inhibition and magnesium-induced enhancement of binding than either the morphine-selective (mu 2) or delta sites. [3H]DSLET binding yielded results very similar to those using [3H]DADL. In conclusion, approximately 80% of [3H]DADL binding in thalamus corresponds to a mu receptor distinct from the classical morphine-selective site. Based upon the results of our studies, we feel that this binding represents mu 1 receptors. DPDPE (10 nM) can effectively inhibit the binding of [3H]DADL to delta receptors, leaving a relatively homogeneous labeling of mu 1 sites. The availability of this selective binding assay should facilitate additional studies of mu 1 receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901663

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  Psychedelics and the human receptorome.

Authors:  Thomas S Ray
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

2.  Affinity labeling mu opioid receptors with novel radioligands.

Authors:  Ke Yang; Amy Zuckerman; Gavril W Pasternak
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

3.  mu opiate receptor: cDNA cloning and expression.

Authors:  J B Wang; Y Imai; C M Eppler; P Gregor; C E Spivak; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

4.  Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer.

Authors:  G D Phillips; T W Robbins; B J Everitt
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

5.  Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.

Authors:  Steven G Grinnell; Susruta Majumdar; Ankita Narayan; Valerie Le Rouzic; Michael Ansonoff; John E Pintar; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2014-06-26       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.